Granulysine

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Cytolytic cytokine formed in the cytolytic granules of activated cytotoxic T cells (CD8) and NK cells. It is active together with the cytokine perforin. Perforin is integrated into the cell membrane of the target cell where it forms a pore-like structure. Certain serine proteases (granzymes) penetrate through this pore into the target cell and induce apoptosis. Granulysin has a broad antimicrobial effect. It leads to the destruction of keratinocytes in certain inflammatory processes of the skin, e.g. in Stevens-Johnson syndrome or TEN. The concentration of granulysin in the bladder contents is directly correlated to the severity of the disease.

LiteratureThis section has been translated automatically.

  1. Chung WH et al (2015) Oxypurinol-Specific T Cells Possess Preferential TCR Clonotypes and Express Granulysin in Allopurinol-Induced Severe Cutaneous Adverse Reactions. J Invest Dermatol doi: 10.1038/yid.2015.165.
  2. Chung WH et al (2014) Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. Ann Rheum Dis PubMed PMID: 25115449.
  3. Su SC et al (2013) Update on pathobiology in Stevens-Johnson syndrome and toxic erpidermal necrolysis. Dermatol Sinica 31: 174-180
  4. Su SC, Chung WH (2014). Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins (Basel) 6:194-210
  5. Cho YT et al (2013) Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. J Am Acad Dermatol 70:539-548

Authors

Last updated on: 29.10.2020